Mentor Worldwide LLC
$2.1M 8,503 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Coherus Biosciences Inc.
Coherus Biosciences Inc. reported $2,156,469.53 across General Payments, Research, and Ownership to 2,945 physicians and teaching hospitals across 3,396 transactions.
- $2.2M Top quartile payer
- All-tracks total
- 3,396 Top quartile volume
- Transactions
- 2,945 Top quartile reach
- Recipients
- −$311.5K
- General Payments vs PY2023
Coherus Biosciences Inc. reported $2,156,469.53 across all CMS Open Payments tracks (General + Research + Ownership) to 2,945 physicians and teaching hospitals in Program Year 2024 - ranking #434 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $361,768.79, averaging $732.25 per recipient.
How Coherus Biosciences Inc.'s $2.2M all-tracks total breaks down
Coherus Biosciences Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
37/100
Total payments
F
30/100
Transaction volume
F
35/100
Physician reach
F
32/100
Payment type diversity
D
50/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer coherus-biosciences-inc Coherus Biosciences Inc.
$2.2M · #434/1,925 · 0.0% industry · PY2024
- TOT $2.2M
- RANK #434
- SHARE 0.0%
- TXN 3,396
- RCP 2,945
- CAT 4
- GEN $361.8K
- ΔGEN −$311.5K
- TOP1 9.0%
- PY 2024
Volume peers
Nearest volume peer: Mentor Worldwide LLC ($2.1M)
Coherus Biosciences Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Coherus Biosciences Inc.'s CMS-reported General Payments decreased by $311.5K (−46.3%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: COHERUS ONCOLOGY, INC.PY2023: COHERUS ONCOLOGY, INC.PY2024: Coherus Biosciences Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $673,277.16
- PY2024
- $361,768.79
What the Data Shows for Coherus Biosciences Inc.
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Coherus Biosciences Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
"Compensation for Services Other Than Consulting" leads the 4-category general-payment breakdown below at $195.8K (54.1% of General Payments, 44 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Across 4 types of general payments, Coherus Biosciences Inc.'s largest category was "Compensation for Services Other Than Consulting" at $195.8K - 54.1% of General Payments.
Coherus Biosciences Inc. reports 4 general-payment categories - the top three are Compensation for Services Other Than Consulting (54.1%), Food and Beverage (23.9%), and Honoraria (14.4%). The remaining 1 category make up 7.5% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Coherus Biosciences Inc. divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Compensation for Services Other Than Consulting | $195.8K | 44 | 54.1% |
| Food and Beverage | $86.6K | 2,808 | 23.9% |
| Honoraria | $52.2K | 32 | 14.4% |
| Travel and Lodging | $27.2K | 61 | 7.5% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $128,014.84 (35.4%) of $361,768.79 in this company's General Payments records across 2,011 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Coherus Biosciences Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Seenu Hariprasad
$32,482.83 across 19 reported transactions
- 2
Panayiotis Savvides
$31,910.55 across 26 reported transactions
- 3
Krzysztof Misiukiewicz
$23,439.19 across 19 reported transactions
- 4
Chaitali Nangia
$21,955.93 across 13 reported transactions
- 5
Shravan Kandula
$18,226.34 across 12 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Coherus Biosciences Inc. ranks #434 of 1,925 by total payments (top 23% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,426 of 1,838 by HHI (bottom 22% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- OPKO Pharmaceuticals, LLC : $235.7K total payments, HHI 350
- Teleflex LLC : $5.6M total payments, HHI 349
- Carl Zeiss Meditec USA, Inc. : $719.3K total payments, HHI 348
- Checkpoint Surgical, Inc : $293.7K total payments, HHI 348
- Medline Industries LP : $1.9M total payments, HHI 347
- Olympus Corporation : $904.0K total payments, HHI 343
- Coherus Biosciences Inc. (this company) : $361.8K total payments, HHI 343
- Orphalan Inc : $61.9K total payments, HHI 342
- Dutch Ophthalmic, USA : $85.0K total payments, HHI 342
- BonaliveInc : $3.3K total payments, HHI 342
- Davol Inc. : $4.4M total payments, HHI 337
- Eli Lilly Export S.A. Puerto Rico Branch : $47.2K total payments, HHI 334
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Coherus Biosciences Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Coherus Biosciences Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Coherus Biosciences Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Akebia Therapeutics Inc
$2.2M 5,560 recipients
Compare payment profiles
Mylan Pharmaceuticals Inc.
$2.2M 8 recipients
Compare payment profiles
Laborie Medical Technologies Corp.
$2.2M 3,675 recipients
Compare payment profiles
MML US, Inc.
$2.1M 2,581 recipients
Compare payment profiles
SiteSaver Inc.
$2.2M 2 recipients
Compare payment profiles
Put this to use
Coherus Biosciences Inc. ranks #434 of 1,925 by all-tracks total payments, led by "Compensation for Services Other Than Consulting".
- See where Coherus Biosciences Inc. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Compensation for Services Other Than Consulting" spend across every manufacturer, not just Coherus Biosciences Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.